Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Burnett

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancerAlessandro D Santin, Eleftherios P Diamandis, Stefania Bellone, et al.
American Journal of Obstetrics and Gynecology|May 2, 2006
Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomasAlessandro D Santin, Eleftherios P Diamandis, Stefania Bellone, et al.
Gynecologic Oncology|October 27, 2005
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalitiesAlessandro D Santin, Stefania Bellone, Michela Palmieri, et al.
Cancer Research|May 19, 2005
Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxinAlessandro D Santin, Stefania Cané, Stefania Bellone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomasAlessandro D Santin, Stefania Bellone, Eric R Siegel, et al.
American Journal of Obstetrics and Gynecology|March 5, 2005
Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancerAlessandro D Santin, Stefania Bellone, Eric R Siegel, et al.
Gynecologic Oncology|May 17, 2005
Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridizationAlessandro D Santin, Stefania Bellone, Sue Van Stedum, et al.
Cancer|August 24, 2005
Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinomaAlessandro D Santin, Stefania Bellone, Sue Van Stedum, et al.
International Journal of Cancer|December 1, 2022
Safe prescribing in cancer patients during the COVID-19 pandemic: A new initiative from the UK Cancer Coronavirus Project (UKCCP) teamNathan Appanna, Grisma Patel, Emma Burke, et al.
BMJ Mental Health|March 31, 2025
Effect of the LifeSpan suicide prevention model on self-harm and suicide in four communities in New South Wales, Australia: a stepped-wedge, cluster randomised controlled trialFiona Shand, Michelle Torok, Andrew Mackinnon, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancerAlessandro D Santin, Eleftherios P Diamandis, Stefania Bellone, et al.
American Journal of Obstetrics and Gynecology|May 2, 2006
Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomasAlessandro D Santin, Eleftherios P Diamandis, Stefania Bellone, et al.
Gynecologic Oncology|October 27, 2005
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalitiesAlessandro D Santin, Stefania Bellone, Michela Palmieri, et al.
Cancer Research|May 19, 2005
Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxinAlessandro D Santin, Stefania Cané, Stefania Bellone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2007
Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomasAlessandro D Santin, Stefania Bellone, Eric R Siegel, et al.
American Journal of Obstetrics and Gynecology|March 5, 2005
Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancerAlessandro D Santin, Stefania Bellone, Eric R Siegel, et al.
Gynecologic Oncology|May 17, 2005
Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridizationAlessandro D Santin, Stefania Bellone, Sue Van Stedum, et al.
Cancer|August 24, 2005
Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinomaAlessandro D Santin, Stefania Bellone, Sue Van Stedum, et al.
International Journal of Cancer|December 1, 2022
Safe prescribing in cancer patients during the COVID-19 pandemic: A new initiative from the UK Cancer Coronavirus Project (UKCCP) teamNathan Appanna, Grisma Patel, Emma Burke, et al.
BMJ Mental Health|March 31, 2025
Effect of the LifeSpan suicide prevention model on self-harm and suicide in four communities in New South Wales, Australia: a stepped-wedge, cluster randomised controlled trialFiona Shand, Michelle Torok, Andrew Mackinnon, et al.
Pageof 4